aspirin has been researched along with Wet Macular Degeneration in 7 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Wet Macular Degeneration: A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.
Excerpt | Relevance | Reference |
---|---|---|
"Aspirin use was not associated significantly with progression to late AMD or its subtypes in either the AREDS or AREDS2." | 2.90 | The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20. ( Agrón, E; Aronow, ME; Chew, EY; Christen, WG; Clemons, TE; Keenan, TD; Wiley, HE, 2019) |
"Most retinal or subretinal hemorrhages in eyes enrolled in CATT were less than 1 DA." | 2.82 | Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. ( Ahmed, O; Daniel, E; Grunwald, JE; Maguire, MG; Martin, DF; Ying, GS, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (85.71) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Lee, WA | 1 |
Yang, YK | 1 |
Cheng, CL | 1 |
Rim, TH | 1 |
Yoo, TK | 1 |
Kwak, J | 1 |
Lee, JS | 1 |
Kim, SH | 1 |
Kim, DW | 1 |
Kim, SS | 1 |
Keenan, TD | 1 |
Wiley, HE | 1 |
Agrón, E | 1 |
Aronow, ME | 1 |
Christen, WG | 1 |
Clemons, TE | 1 |
Chew, EY | 1 |
Sobrin, L | 1 |
Seddon, JM | 1 |
de Jong, PT | 2 |
Wang, JJ | 1 |
Fletcher, AE | 2 |
Ying, GS | 1 |
Maguire, MG | 1 |
Daniel, E | 1 |
Grunwald, JE | 1 |
Ahmed, O | 1 |
Martin, DF | 1 |
Chakravarthy, U | 1 |
Rahu, M | 1 |
Seland, J | 1 |
Soubrane, G | 1 |
Topouzis, F | 1 |
Vingerling, JR | 1 |
Vioque, J | 1 |
Young, I | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)[NCT00593450] | Phase 3 | 1,208 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT00593450)
Timeframe: at 1 Year
Intervention | mm^2 (Mean) |
---|---|
1-Lucentis Monthly | 6.6 |
2-Avastin Monthly | 6.5 |
3-Lucentis as Needed | 7.3 |
4-Avastin as Needed | 7.0 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | mm^2 (Mean) |
---|---|
1-Lucentis Monthly | -0.1 |
2-Avastin Monthly | 0.3 |
3-Lucentis as Needed | 0.6 |
4-Avastin as Needed | 1.3 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | US dollars per patient (Mean) |
---|---|
1-Lucentis Monthly | 23400 |
2-Avastin Monthly | 595 |
3-Lucentis as Needed | 13800 |
4-Avastin as Needed | 385 |
"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.~In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement." (NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | No. of Letters (Mean) |
---|---|
1-Lucentis Monthly | 8.5 |
2-Avastin Monthly | 8.0 |
3-Lucentis as Needed | 6.8 |
4-Avastin as Needed | 5.9 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | mm Hg (Mean) |
---|---|
1-Lucentis Monthly | -0.9 |
2-Avastin Monthly | -1.4 |
3-Lucentis as Needed | -1.9 |
4-Avastin as Needed | -2.1 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | mm Hg (Mean) |
---|---|
1-Lucentis Monthly | -2.1 |
2-Avastin Monthly | -5.4 |
3-Lucentis as Needed | -5.2 |
4-Avastin as Needed | -4.5 |
Cumulative over the 1 year of trial (NCT00593450)
Timeframe: 1 Year
Intervention | Number of Treatments (Mean) |
---|---|
1-Lucentis Monthly | 11.7 |
2-Avastin Monthly | 11.9 |
3-Lucentis as Needed | 6.9 |
4-Avastin as Needed | 7.7 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | μm (Mean) |
---|---|
1-Lucentis Monthly | 152 |
2-Avastin Monthly | 172 |
3-Lucentis as Needed | 166 |
4-Avastin as Needed | 172 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | μm (Mean) |
---|---|
1-Lucentis Monthly | -100 |
2-Avastin Monthly | -79 |
3-Lucentis as Needed | -81 |
4-Avastin as Needed | -79 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | μm (Mean) |
---|---|
1-Lucentis Monthly | 266 |
2-Avastin Monthly | 300 |
3-Lucentis as Needed | 294 |
4-Avastin as Needed | 308 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | μm (Mean) |
---|---|
1-Lucentis Monthly | -196 |
2-Avastin Monthly | -164 |
3-Lucentis as Needed | -168 |
4-Avastin as Needed | -152 |
"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.~In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity." (NCT00593450)
Timeframe: at 1 Year
Intervention | No. of Letters (Mean) |
---|---|
1-Lucentis Monthly | 68.8 |
2-Avastin Monthly | 68.4 |
3-Lucentis as Needed | 68.4 |
4-Avastin as Needed | 66.5 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | Participants (Number) | ||||
---|---|---|---|---|---|
Increase of ≥15 letters | Increase of 5-14 letters | Change of ≤4 letters | Decrease of 5-14 letters | Decrease of ≥15 letters | |
1-Lucentis Monthly | 97 | 90 | 62 | 19 | 16 |
2-Avastin Monthly | 83 | 98 | 50 | 18 | 16 |
3-Lucentis as Needed | 71 | 103 | 75 | 23 | 13 |
4-Avastin as Needed | 76 | 90 | 59 | 23 | 23 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | Participants (Number) | ||
---|---|---|---|
Absent | Present | Data missing | |
1-Lucentis Monthly | 167 | 97 | 20 |
2-Avastin Monthly | 153 | 100 | 12 |
3-Lucentis as Needed | 133 | 137 | 15 |
4-Avastin as Needed | 111 | 145 | 15 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | Participants (Number) | ||
---|---|---|---|
Absent | Present | Data missing | |
1-Lucentis Monthly | 124 | 151 | 9 |
2-Avastin Monthly | 69 | 188 | 8 |
3-Lucentis as Needed | 68 | 203 | 14 |
4-Avastin as Needed | 52 | 214 | 5 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | Participants (Number) | ||||
---|---|---|---|---|---|
83-97 letters, 20/12-20 | 68-82 letters, 20/25-40 | 53-67 letters, 20/50-80 | 38-52 letters, 20/100-160 | ≤37 letters, ≤20/200 | |
1-Lucentis Monthly | 42 | 149 | 52 | 23 | 18 |
2-Avastin Monthly | 45 | 134 | 47 | 21 | 18 |
3-Lucentis as Needed | 38 | 141 | 66 | 23 | 17 |
4-Avastin as Needed | 40 | 127 | 57 | 24 | 23 |
2 trials available for aspirin and Wet Macular Degeneration
Article | Year |
---|---|
The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dis | 2019 |
Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Bevacizumab; Cardiovascul | 2016 |
5 other studies available for aspirin and Wet Macular Degeneration
Article | Year |
---|---|
Risk of age-related macular degeneration in aspirin users and non-aspirin users: A population-based cohort study in Taiwan.
Topics: Angiogenesis Inhibitors; Aspirin; Cohort Studies; Humans; Incidence; Middle Aged; Retrospective Stud | 2021 |
Long-Term Regular Use of Low-Dose Aspirin and Neovascular Age-Related Macular Degeneration: National Sample Cohort 2010-2015.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; | 2019 |
Regular aspirin use and risk of age-related macular degeneration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Risk Factors; Wet Macular Degeneration | 2013 |
Aspirin use and aging macula disorder.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Risk Assessment; | 2014 |
Associations between aspirin use and aging macula disorder: the European Eye Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cholesterol; Cross- | 2012 |